Metsera bulks up cash pile for shot at obesity

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series B financing to further advance its portfolio of clinical-stage, nutrient-stimulated hormone (NuSH) analog peptides.

The funding round, which was led by Wellington Management and Venrock Healthcare Capital Partners, comes only seven months after Metsera’s high-profile debut with $290 million in initial capital, taking the total raised by the company beyond $500 million.

Phase II trials of Metsera’s ultra-long acting, fully-biased injectable GLP-1 RA are underway. The company recently reported significant and durable weight loss from the Phase I/II trial of MET-097i, which was engineered with its HALO lipidation platform.